Exagen Inc
NASDAQ:XGN

Watchlist Manager
Exagen Inc Logo
Exagen Inc
NASDAQ:XGN
Watchlist
Price: 7.11 USD -1.39% Market Closed
Market Cap: 161.1m USD

Wall Street
Price Targets

XGN Price Targets Summary
Exagen Inc

Wall Street analysts forecast XGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XGN is 15.74 USD with a low forecast of 12.12 USD and a high forecast of 18.9 USD.

Lowest
Price Target
12.12 USD
70% Upside
Average
Price Target
15.74 USD
121% Upside
Highest
Price Target
18.9 USD
166% Upside
Exagen Inc Competitors:
Price Targets
300896
Imeik Technology Development Co Ltd
43% Upside
ALXO
ALX Oncology Holdings Inc
108% Upside
RPTX
Repare Therapeutics Inc
43% Upside
RCKT
Rocket Pharmaceuticals Inc
137% Upside
FOLD
Amicus Therapeutics Inc
59% Upside
068270
Celltrion Inc
18% Upside
301080
Acrobiosystems Co Ltd
39% Upside
BBIO
BridgeBio Pharma Inc
13% Upside

Revenue
Forecast

Revenue Estimate
Exagen Inc

For the last 11 years the compound annual growth rate for Exagen Inc's revenue is 30%. The projected CAGR for the next 4 years is 16%.

30%
Past Growth
16%
Estimated Growth
Estimates Accuracy
2%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Exagen Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Net Income
Forecast

Net Income Estimate
Exagen Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-31%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is XGN's stock price target?
Price Target
15.74 USD

According to Wall Street analysts, the average 1-year price target for XGN is 15.74 USD with a low forecast of 12.12 USD and a high forecast of 18.9 USD.

What is Exagen Inc's Revenue forecast?
Projected CAGR
16%

For the last 11 years the compound annual growth rate for Exagen Inc's revenue is 30%. The projected CAGR for the next 4 years is 16%.

Back to Top